Pfenex Inc.
PFNX evidence brief
What we can confirm
- BioSniper Score:
- 7.7 / 10
- Lead Asset:
- pf708 (BLA Filed)
What it means
What to watch
Prepared research question
What matters most for PFNX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
pf708 (BLA Filed)
Next Catalyst
—
Tracking 3 pipeline candidates for Pfenex Inc..
Run Pfenex Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Pfenex Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: BLA Filed
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is Pfenex Inc.'s lead drug candidate?
Pfenex Inc.'s most advanced tracked candidate is pf708 (BLA Filed) for osteoporosis.
Who is the CEO of Pfenex Inc.?
California April is the chief executive officer of Pfenex Inc. (PFNX).
What therapeutic areas does Pfenex Inc. focus on?
Pfenex Inc. develops therapies across Oncology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.